🔗 Share this article

While America continues making sweeping adjustments to its immunization schedules, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccinations during the global health crisis and has zeroed in on alleged fatalities following Covid vaccination in her brief position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities were set to announce sweeping revisions to the pediatric immunization program in December, aligning the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of step with a large portion of the international standard with little proof for benefit. The announcement has been postponed until the new year.

In place of Vinay Prasad, Høeg is scheduled to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A Shift at the FDA

The acting appointment might represent a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for ending certain childhood vaccine recommendations in the US so as to align more similar to Denmark, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, head of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Høeg has no apparent background in pharmaceutical research, approval processes or leadership, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Former directors of CBER would “grasp regulatory frameworks and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

The drug center has an immense workload at the FDA, the former commissioner stated.

“Many people just focuses on the new drug program, but the generic program clears thousands of generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and each of these must be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a significant management component to the job, which supervises over 5,000 staff members. “It is a huge management job, if you perform it correctly,” she said.

Official Statement and Disputed Initiatives

In response to concerns about Dr. Høeg's qualifications and whether this selection signifies greater collaboration among agency officials on vaccines, a press secretary stated that the “concerns are based on incorrect presumptions”.

“Her resume aligns with the duties of her role,” the spokesperson said, pointing to the time Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the agency head's recently launched priority voucher program, a disputed one-day drug-approval program that reportedly concerned her predecessors. “How are these drugs being selected for this voucher program? Who is making the calls?” Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards more relaxed regulations of all drugs, with the exception of shots.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if troubling, track record, some experts observe. She authored a study using non-validated crowd-sourced reports to determine the incidence of heart inflammation following Covid vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the new federal leadership featured revising guidelines for new vaccines and halting “non-essential” vaccines, she said post-election on a online show. At the agency, Høeg has reportedly floated the idea of barring adolescent males from getting Covid vaccines.

“She’s an complete true believer who starts off with her preconceived notions and tailors the evidence to accommodate the science in a very misleading, dishonest way,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg aligned with other contrarians, {like|